KR102307053B1 - (6S,9aS)-N-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1H-피라지노[2,1-c][1,2,4]트리아진-1-카복사미드 화합물 - Google Patents

(6S,9aS)-N-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1H-피라지노[2,1-c][1,2,4]트리아진-1-카복사미드 화합물 Download PDF

Info

Publication number
KR102307053B1
KR102307053B1 KR1020167015608A KR20167015608A KR102307053B1 KR 102307053 B1 KR102307053 B1 KR 102307053B1 KR 1020167015608 A KR1020167015608 A KR 1020167015608A KR 20167015608 A KR20167015608 A KR 20167015608A KR 102307053 B1 KR102307053 B1 KR 102307053B1
Authority
KR
South Korea
Prior art keywords
methyl
compound
azetidin
prepared
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167015608A
Other languages
English (en)
Korean (ko)
Other versions
KR20160094980A (ko
Inventor
사토시 이노우에
유지 야마모토
겐타로 이소
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
가부시키가이샤 프리즘 바이오랩
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤, 가부시키가이샤 프리즘 바이오랩 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20160094980A publication Critical patent/KR20160094980A/ko
Application granted granted Critical
Publication of KR102307053B1 publication Critical patent/KR102307053B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020167015608A 2013-12-25 2014-12-22 (6S,9aS)-N-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1H-피라지노[2,1-c][1,2,4]트리아진-1-카복사미드 화합물 Active KR102307053B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013267687 2013-12-25
JPJP-P-2013-267687 2013-12-25
PCT/JP2014/083932 WO2015098853A1 (ja) 2013-12-25 2014-12-22 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物

Publications (2)

Publication Number Publication Date
KR20160094980A KR20160094980A (ko) 2016-08-10
KR102307053B1 true KR102307053B1 (ko) 2021-10-01

Family

ID=53399298

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015608A Active KR102307053B1 (ko) 2013-12-25 2014-12-22 (6S,9aS)-N-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1H-피라지노[2,1-c][1,2,4]트리아진-1-카복사미드 화합물

Country Status (34)

Country Link
US (1) US9174998B2 (https=)
EP (1) EP3088401B1 (https=)
JP (1) JP6085040B2 (https=)
KR (1) KR102307053B1 (https=)
CN (1) CN105873932B (https=)
AR (1) AR098908A1 (https=)
AU (1) AU2014371148B2 (https=)
BR (1) BR112016013572B1 (https=)
CA (1) CA2932435C (https=)
CL (1) CL2016001419A1 (https=)
CY (1) CY1122521T1 (https=)
DK (1) DK3088401T3 (https=)
ES (1) ES2728353T3 (https=)
HR (1) HRP20190908T1 (https=)
HU (1) HUE044541T2 (https=)
IL (1) IL245961A0 (https=)
JO (1) JO3809B1 (https=)
LT (1) LT3088401T (https=)
ME (1) ME03391B (https=)
MX (1) MX365376B (https=)
MY (1) MY173946A (https=)
PE (1) PE20160932A1 (https=)
PH (1) PH12016501079A1 (https=)
PL (1) PL3088401T3 (https=)
PT (1) PT3088401T (https=)
RS (1) RS58955B1 (https=)
RU (1) RU2669805C2 (https=)
SG (1) SG11201604496YA (https=)
SI (1) SI3088401T1 (https=)
SM (1) SMT201900306T1 (https=)
TR (1) TR201908392T4 (https=)
TW (1) TWI681961B (https=)
UA (1) UA116923C2 (https=)
WO (1) WO2015098853A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) * 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CA2986999C (en) * 2015-06-23 2023-08-08 Eisai R&D Management Co., Ltd. Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
CN108084067B (zh) * 2016-11-22 2019-08-30 重庆圣华曦药业股份有限公司 一种立他司特中间体的制备方法
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
MX2022005056A (es) 2019-10-29 2022-05-18 Eisai R&D Man Co Ltd Combinacion de un antagonista de pd-1, un inhibidor tirosina cinasa de vegfr/fgfr/ret y un inhibidor de cbp/beta-catenina para el tratamiento del cancer.
AR121544A1 (es) 2020-03-12 2022-06-15 3 2 Pharma Inhibidores de la vía de señalización por cbp / catenina y sus usos
WO2021183791A1 (en) 2020-03-12 2021-09-16 City Of Hope Wnt/cbp/catenin signaling pathway inhibitors and uses thereof
US20230390296A1 (en) 2020-10-30 2023-12-07 Keio University Novel treatment and prevention of sarcopenia-related diseases
US20240352020A1 (en) * 2021-08-26 2024-10-24 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
MX2024002060A (es) * 2021-09-08 2024-03-01 Eisai R&D Man Co Ltd Composicion farmaceutica para tratar tumores solidos.
CN116262120A (zh) * 2021-12-13 2023-06-16 上海中医药大学 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用
WO2023140369A1 (en) * 2022-01-18 2023-07-27 Prism BioLab Co., Ltd. Phosphoric acid derivatives
US20250177406A1 (en) 2022-03-31 2025-06-05 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN115784934A (zh) * 2022-11-22 2023-03-14 上海吉奉生物科技有限公司 一种酪氨酸衍生物的合成方法
JPWO2024209717A1 (https=) 2023-04-06 2024-10-10
WO2025174646A1 (en) * 2024-02-12 2025-08-21 Albert Einstein College Of Medicine Inhibitors of beta-catenin c-terminal domain and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500666A (ja) 2007-10-15 2011-01-06 チュンウェ ファーマ コーポレーション リバースターン類似体の新規化合物およびその用途（３）
JP2011522037A (ja) 2008-06-06 2011-07-28 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 アルファへリックスミメティック及び関連の方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444235B1 (en) * 2001-10-12 2008-06-11 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CN102459271B (zh) * 2009-04-15 2014-07-02 Jw制药公司 回折模拟物的新化合物及其制备方法和用途
CN103209982B (zh) * 2010-10-14 2016-03-16 Jw制药公司 反转模拟物的化合物、其制造方法及其用途
US20140051706A1 (en) * 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500666A (ja) 2007-10-15 2011-01-06 チュンウェ ファーマ コーポレーション リバースターン類似体の新規化合物およびその用途（３）
JP2011522037A (ja) 2008-06-06 2011-07-28 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 アルファへリックスミメティック及び関連の方法

Also Published As

Publication number Publication date
PT3088401T (pt) 2019-06-12
AR098908A1 (es) 2016-06-22
LT3088401T (lt) 2019-07-25
EP3088401A4 (en) 2017-06-28
PE20160932A1 (es) 2016-09-10
IL245961A0 (en) 2016-08-02
SI3088401T1 (sl) 2019-08-30
US20150175615A1 (en) 2015-06-25
SMT201900306T1 (it) 2019-07-11
PH12016501079A1 (en) 2016-07-11
UA116923C2 (uk) 2018-05-25
BR112016013572B1 (pt) 2023-03-21
RU2016122867A (ru) 2018-02-01
EP3088401B1 (en) 2019-03-06
ES2728353T3 (es) 2019-10-23
RS58955B1 (sr) 2019-08-30
BR112016013572A2 (https=) 2017-10-03
RU2669805C2 (ru) 2018-10-16
WO2015098853A1 (ja) 2015-07-02
EP3088401A1 (en) 2016-11-02
PL3088401T3 (pl) 2019-09-30
NZ720718A (en) 2020-10-30
HUE044541T2 (hu) 2019-10-28
MY173946A (en) 2020-02-28
CA2932435A1 (en) 2015-07-02
RU2016122867A3 (https=) 2018-06-18
AU2014371148B2 (en) 2018-08-09
DK3088401T3 (da) 2019-06-03
AU2014371148A1 (en) 2016-06-23
ME03391B (me) 2020-01-20
TR201908392T4 (tr) 2019-07-22
JPWO2015098853A1 (ja) 2017-03-23
KR20160094980A (ko) 2016-08-10
CN105873932B (zh) 2017-11-24
US9174998B2 (en) 2015-11-03
CL2016001419A1 (es) 2017-01-20
CA2932435C (en) 2021-08-17
TW201609736A (zh) 2016-03-16
CN105873932A (zh) 2016-08-17
HK1222656A1 (zh) 2017-07-07
HRP20190908T1 (hr) 2019-08-09
JO3809B1 (ar) 2021-01-31
CY1122521T1 (el) 2021-01-27
JP6085040B2 (ja) 2017-02-22
TWI681961B (zh) 2020-01-11
MX2016007705A (es) 2017-01-11
MX365376B (es) 2019-05-31
SG11201604496YA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
KR102307053B1 (ko) (6S,9aS)-N-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1H-피라지노[2,1-c][1,2,4]트리아진-1-카복사미드 화합물
KR102505664B1 (ko) Ezh2 저해제　및　e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물
KR102638678B1 (ko) 헤테로시클릭 화합물
KR102559211B1 (ko) (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정
KR20220086573A (ko) 융합된 피리돈 화합물, 및 이의 제조 방법 및 이의 용도
NZ713233A (en) Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
BR112019015269A2 (pt) compostos
JP2023502279A (ja) Ｃｐｓ１を阻害するためのピペラジン化合物
HK1222656B (en) (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazine-1-yl)azetidine-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
NZ720718B2 (en) (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
NZ713233B2 (en) (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160613

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190813

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210118

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210629

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210916

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210924

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240913

Start annual number: 4

End annual number: 4